Celsis Adds Drug Development Services to Growing Services Portfolio
Complete the form below to unlock access to ALL audio articles.
Celsis International plc has announces the addition of Drug Development Services to its growing services portfolio. These new service offerings, which include ADME-Tox studies and preclinical and clinical CMC development services, are part of the company’s long-term strategy to offer comprehensive products and services to accelerate drug discovery and development.
Thirty percent of new drugs fail in the development pipeline due to toxicity profiles and side effects. By evaluating a pharmaceutical molecule’s ADME (absorption, distribution, metabolism, and excretion) properties and potential toxicity, ADME-Tox screening assays help to optimize the number of drug candidates for further development.
“Our goal is to save our customers both time and money by delivering the highest quality ADME-Tox services coupled with the best customer service and turnaround time in the industry,” said John Daniels, Vice President and General Manager of Celsis Analytical Services. “With our expanded services, we offer customers a continuum of technical expertise from pre-clinical testing through market launch.”
Since 1990, In Vitro Technologies Inc. (IVT) provided ADME-Tox products and services to pharmaceutical and biotechnology companies. Celsis’ new services became available after its acquisition of IVT in June 2006. Celsis has since expanded its service offerings, invested in instrumentation and upgraded its quality platform to GLP and GMP levels. These upgrades will be part of the company’s newly formed Development Services group, an extension of Celsis’ Analytical Services division.
The ADME-Tox services focus on in vitro drug metabolism, drug-drug interactions, permeability, absorption, organ toxicity, and plasma protein binding.
In addition, Celsis Development Services will offer CMC drug development services to serve clients from discovery through all clinical phases of drug development. CMC services will include preformulation and formulation development to provide comprehensive insight into the physicochemical properties of a drug molecule and its product formulations.
